DoriNano, Inc.

DoriNano has developed a method to precisely space multiple different biological payloads at the nanoscale on a delivery vehicle (DNA Origami). Preclinical evidence from the DoriNano team demonstrates that nanoscale difference in the spacing of payloads impacts receptor binding affinity and downstream activity, leading to enhanced immune responses while reducing required dosages by 10-100 fold compared to traditional methods and opening up an entirely new modality for tuning drug efficacy. DoriNano is initially focusing on the development of a cancer vaccine for head and neck squamous cell carcinoma (HNSCC) with plans to expand to other cancer types.